Screener
uniQure QURE Hemgenix — Other Expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by uniQure in its filing.
Tagged under the XBRL concept us-gaap:OtherExpenses.
The source filing: uniQure’s 10-K, filed March 2, 2026.
- Filed
- Mar 2, 2026, 7:24 AM EST
- Fiscal year
- FY2025
- Accession
- 0001104659-26-021898
In the years ended December 31, 2025 and 2024, the Company recognized $6.3 million and $3.2 million, respectively (nil in the period ended December 31, 2023) in Other expense related to the purchase of HEMGENIX from Genezen, net of income from the sales of HEMGENIX to CSL Behring, amortization of the intangible asset for the favorable supply terms under the CSA and credits from the release of liabilities related to expected net losses associated with the minimum purchase commitments under the CSA.
Item 16. Form 10-K Summary
FAQ
- What is uniQure's hemgenix — other expenses?
- uniQure (QURE) reported hemgenix — other expenses of $1.58M in Q4 2025.
- How has uniQure's hemgenix — other expenses changed year-over-year?
- uniQure's hemgenix — other expenses increased by 96.9% year-over-year, from $800K to $1.58M.
- What does hemgenix — other expenses mean?
- This metric captures ancillary operational costs specifically attributable to the Hemgenix product line that fall outside of standard direct manufacturing or research and development categories. These expenses typically include product-specific logistics, regulatory compliance fees, or specialized marketing and distribution support required for commercialization. Tracking these costs provides insight into the non-production overhead required to support the market presence and lifecycle management of the therapy.
Ask your AI about uniQure's hemgenix — other expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude